Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance.

2.50
Hdl Handle:
http://hdl.handle.net/10146/36512
Title:
Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance.
Authors:
Gormally, Emmanuelle; Caboux, Elodie; Vineis, Paolo; Hainaut, Pierre
Abstract:
The presence of small amounts of tumor DNA in cell free DNA (CFDNA) circulating in the plasma or serum of cancer patients was first demonstrated 30 years ago. Since then, overall plasma DNA concentration in cancer patients and genetic or epigenetic alterations specific to tumor DNA have been investigated in patients diagnosed with different types of cancer. The proportion of patients with altered CFDNA varies with the pathology and the nature of the marker. However, several studies have reported the presence of altered CFDNA in over 50% of cancer patients, suggesting that this marker may be common and amenable for a variety of clinical and epidemiological studies. Because the mechanisms and timing of CFDNA release in the blood stream are poorly understood, only few studies have addressed the use of CFDNA for early cancer detection or as a biomarker for mutagenesis and tumourigenesis in molecular epidemiology. In this review, we discuss the technical issues involved in obtaining, using and analyzing CFDNA in cancer or healthy subjects. We also summarize the literature available on the mechanisms of CDNA release as well as on cross-sectional or prospective studies aimed at assessing the clinical and biological significance of CFDNA. These studies show that, in some circumstances, CFDNA alterations are detectable ahead of cancer diagnosis, raising the possibility of exploiting them as biomarkers for monitoring cancer occurrence. Testing these hypotheses will require well-designed studies, assessing multiple markers with quantitative and sensitive methods, with adequate follow-up of subjects, and we provide recommendations for the development of such studies.
Citation:
Mutat. Res. 635 (2-3):105-117
Journal:
Mutation Research
Issue Date:
27-Aug-2008
URI:
http://hdl.handle.net/10146/36512
DOI:
10.1016/j.mrrev.2006.11.002
PubMed ID:
17257890
Additional Links:
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T2G-4MWY06S-1&_user=1843694&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000055040&_version=1&_urlVersion=0&_userid=1843694&md5=708c6d527c0e1e66954c56402a301a81
Type:
Article
Language:
en
ISSN:
0027-5107
Sponsors:
he authors of this paper are partners of European Cancer Risk, Nutrition and Individual Susceptibility (ECNIS), a network of excellence operating within the European Union 6th Framework Program, Priority 5: “Food Quality and Safety” (Contract No. 513943). The work on plasma DNA at IARC was partially supported by the Compagnia di San Paolo (Torino, Italy), the Lega Italiana per la lotta contro I tumori and the European Community (GENAIR programme, QL4-1999-000927).
Appears in Collections:
Articles

Full metadata record

DC FieldValue Language
dc.contributor.authorGormally, Emmanuelle-
dc.contributor.authorCaboux, Elodie-
dc.contributor.authorVineis, Paolo-
dc.contributor.authorHainaut, Pierre-
dc.date.accessioned2008-08-27T09:07:06Z-
dc.date.available2008-08-27T09:07:06Z-
dc.date.issued2008-08-27T09:07:06Z-
dc.identifier.citationMutat. Res. 635 (2-3):105-117en
dc.identifier.issn0027-5107-
dc.identifier.pmid17257890-
dc.identifier.doi10.1016/j.mrrev.2006.11.002-
dc.identifier.urihttp://hdl.handle.net/10146/36512-
dc.description.abstractThe presence of small amounts of tumor DNA in cell free DNA (CFDNA) circulating in the plasma or serum of cancer patients was first demonstrated 30 years ago. Since then, overall plasma DNA concentration in cancer patients and genetic or epigenetic alterations specific to tumor DNA have been investigated in patients diagnosed with different types of cancer. The proportion of patients with altered CFDNA varies with the pathology and the nature of the marker. However, several studies have reported the presence of altered CFDNA in over 50% of cancer patients, suggesting that this marker may be common and amenable for a variety of clinical and epidemiological studies. Because the mechanisms and timing of CFDNA release in the blood stream are poorly understood, only few studies have addressed the use of CFDNA for early cancer detection or as a biomarker for mutagenesis and tumourigenesis in molecular epidemiology. In this review, we discuss the technical issues involved in obtaining, using and analyzing CFDNA in cancer or healthy subjects. We also summarize the literature available on the mechanisms of CDNA release as well as on cross-sectional or prospective studies aimed at assessing the clinical and biological significance of CFDNA. These studies show that, in some circumstances, CFDNA alterations are detectable ahead of cancer diagnosis, raising the possibility of exploiting them as biomarkers for monitoring cancer occurrence. Testing these hypotheses will require well-designed studies, assessing multiple markers with quantitative and sensitive methods, with adequate follow-up of subjects, and we provide recommendations for the development of such studies.en
dc.description.sponsorshiphe authors of this paper are partners of European Cancer Risk, Nutrition and Individual Susceptibility (ECNIS), a network of excellence operating within the European Union 6th Framework Program, Priority 5: “Food Quality and Safety” (Contract No. 513943). The work on plasma DNA at IARC was partially supported by the Compagnia di San Paolo (Torino, Italy), the Lega Italiana per la lotta contro I tumori and the European Community (GENAIR programme, QL4-1999-000927).en
dc.language.isoenen
dc.relation.urlhttp://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T2G-4MWY06S-1&_user=1843694&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000055040&_version=1&_urlVersion=0&_userid=1843694&md5=708c6d527c0e1e66954c56402a301a81en
dc.subjectCirculating free DNAen
dc.subjectMolecular epidemiologyen
dc.subjectCarcinogenesisen
dc.subjectbiomarkersen
dc.subject.meshDNA, Neoplasm-
dc.subject.meshEpidemiology, Molecular-
dc.subject.meshHumans-
dc.subject.meshNeoplasms-
dc.subject.meshPredictive Value of Tests-
dc.subject.meshTumor Markers, Biological-
dc.titleCirculating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance.en
dc.typeArticleen
dc.identifier.journalMutation Researchen

Related articles on PubMed

All Items in ECNIS-NIOM are protected by copyright, with all rights reserved, unless otherwise indicated.